Arcturus Therapeutics Holdings Inc. (ARCT): Price and Financial Metrics

Arcturus Therapeutics Holdings Inc. (ARCT)

Today's Latest Price: $40.09 USD

2.60 (6.94%)

Updated Sep 25 4:00pm

Add ARCT to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ARCT Stock Summary

  • With a one year PEG ratio of 0.17, Arcturus Therapeutics Holdings Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than only 4.16% of US stocks.
  • ARCT's price/sales ratio is 86.88; that's higher than the P/S ratio of 97.01% of US stocks.
  • As for revenue growth, note that ARCT's revenue has grown -45.87% over the past 12 months; that beats the revenue growth of only 4.56% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Arcturus Therapeutics Holdings Inc are LOGC, EVGN, ORMP, CRIS, and PULM.
  • Visit ARCT's SEC page to see the company's official filings. To visit the company's web site, go to
ARCT Daily Price Range
ARCT 52-Week Price Range

ARCT Stock Price Chart Technical Analysis Charts

ARCT Price/Volume Stats

Current price $40.09 52-week high $66.24
Prev. close $37.49 52-week low $8.51
Day low $37.12 Volume 420,859
Day high $40.84 Avg. volume 584,771
50-day MA $49.93 Dividend yield N/A
200-day MA $30.86 Market Cap 977.71M

Arcturus Therapeutics Holdings Inc. (ARCT) Company Bio

Arcturus Therapeutics Ltd a biopharmaceutical company, focuses on the development and commercialization of oral drug candidates. The company was founded in 2008 and is based in Tel Aviv, Israel.

ARCT Latest News Stream

Event/Time News Detail
Loading, please wait...

ARCT Latest Social Stream

Loading social stream, please wait...

View Full ARCT Social Stream

Latest ARCT News From Around the Web

Below are the latest news stories about Arcturus Therapeutics Holdings Inc that investors may wish to consider to help them evaluate ARCT as an investment opportunity.

Stock-Specific Ideas for the Post-Fed Era of Investing

First and foremost, the market didn't hear what it wanted from Federal Reserve Chair Jerome Powell. One way to "punt" on that difficult question is to buy Catalent -- recently added to the S&P 500 to the chagrin of Tesla bulls -- which has manufacturing agreements with Arcturus, Moderna and AstraZeneca, among others.

Yahoo | September 18, 2020

Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will be presenting at upcoming investor and scientific conferences virtually: * TIDES: Oligonucleotide and Peptide Therapeutics scientific conference Presentation Date: Wednesday, September 9, 2020 Time: On-line * Baird Global Healthcare Conference Presentation Date: Wednesday, September 9, 2020 Time: 1:25 p.m. ET * Citi 15th Annual BioPharma Conference Panel Date: Thursday, September 10, 2020 Time: 1:30 p.m. ET * UBS ...

Yahoo | September 8, 2020

Arcturus Therapeutics Ltd. (ARCT) Investor Presentation - Slideshow

The following slide deck was published by Arcturus Therapeutics Holdings Inc. in conjunction with this event....

SA Transcripts on Seeking Alpha | September 3, 2020

LD Micro: 360 Companies - Set to Present this Week

LOS ANGELES, CA / ACCESSWIRE / August 31, 2020 / LD Micro today announced the final list of companies slated to present at the upcoming LD 500, taking place September 1st-4th, 2020, exclusively online.

Yahoo | August 31, 2020

When Will Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Turn A Profit?

With the business potentially at an important milestone, we thought we'd take a closer look at Arcturus Therapeutics...

Yahoo | August 30, 2020

Read More 'ARCT' Stories Here

ARCT Price Returns

1-mo -23.33%
3-mo -14.67%
6-mo 195.00%
1-year 284.74%
3-year 467.04%
5-year -3.26%
YTD 268.81%
2019 139.96%
2018 -43.02%
2017 -45.92%
2016 -66.56%
2015 68.36%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7156 seconds.